It was also reported that the knockdown of beta-catenin can restore the response to crizotinib in neuroblastoma [50], which may support the observed positive effect of beta-catenin deficiency in our cohort and imply a strategy of combining inhibitors against beta-catenin and MET/ALK. This evidence concerns the gene MET and neuroblastoma.